Supreme Court (SC) has issued a notice to the Centre and Ranbaxy on a PIL (Public Interest Litigation) seeking probe against the company for allegedly supplying adulterated drugs in the country. However, the SC has refused to pass an interim order to restrain the company from manufacturing drugs. This was the first time the pharma company has been penalised domestically.
If a ban is imposed on the drug, then the company is likely to lose Rs 76 crore revenue. The company is already reeling under USFDA (United States Food and Drugs Administration) imposed restrictions on all its plants. The company had last year pleaded guilty to charges related to drug safety and agreed to pay $500 million in fines under a settlement agreement with the US Department of Justice.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
